Assessing the real-world safety of fenofibric acid for hyperlipidemia: results from WHO-VigiAccess and FAERS databases.

ABSTRACT:

Background

Fenofibric acid is a small-molecule fibrate that functions as an agonist of peroxisome proliferator-activated receptor alpha (PPARα) and serves as an inhibitor of liver fatty acid-binding protein. It is primarily prescribed for the management of hyperlipidemia, including conditions such as hypercholesterolemia and hypertriglyceridemia. As a lipid-lowering agent, a comprehensive understanding of the real-world safety profile of fenofibric acid is essential to ensure its safe and effective use in clinical practice.

Methods

This study utilizes four disproportionality analysis methods to investigate adverse event (AE) reports related to fenofibric acid in the WHO VigiAccess and FDA Adverse Event Reporting System (FAERS) databases, thereby providing robust scientific e

SUBMITTER: Li Y 

PROVIDER: S-EPMC12634654 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature